Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions.
Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is eligible to receive up to $2.1 billion in upfront and milestone payments, along with tiered royalties tied to future net sales, according to a Feb. 25 news release.
The collaboration aims to enable oral delivery of peptide and protein therapeutics that are typically limited to injections because of low gastrointestinal absorption. Vivtex’s platform combines high-throughput gastrointestinal screening, drug delivery technologies and AI-driven analytics designed to improve oral bioavailability and performance.
Novo Nordisk will lead global development, regulatory activities, manufacturing and commercialization of any resulting products.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
